Pharmacokinetics, Pharmacodynamics, & Drug Metabolism Community

Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding - The AAPS Journal SpringerLink remove preview Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding - The AAPS Journal The antiparasitic drug nifurtimox was approved in the USA in 2020 for the treatment of patients with Chagas disease aged less than 18 years and weighing at least 2.5 kg, based on outcomes from the phase 3 CHICO study. Accordingly, pediatric patients with Chagas disease take nifurtimox thrice daily with food at one of two body weight-adjusted dose ranges. View this on SpringerLink >

To view the full article through your AAPS membership:

Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal 

Enter your AAPS credentials

Click "Member Access to Journals"

Click on the The AAPS Journal cover.

Copy and paste the url into the "Search" box, and click search

The full article should appear.

------------------------------
Ho-Leung Fung Ph.D., FAAPS
Editor-in-Chief
University at Buffalo
Sarasota FL
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------